News

Achieve Life Sciences announces pricing of $45.0 million underwritten public offering. Learn more:

With @Omnicom, we've outlined a launch strategy for the first potential new treatment for nicotine dependence in 20 years. With proven, cross-industry insights, we aim to set a ...new standard for biotech and help millions who want to quit.

Learn more: https://bit.ly/AchieveOmnicom

Today, Achieve announced that it has submitted a New Drug Application to the @US_FDA for cytisinicline as a treatment of nicotine dependence for smoking cessation. We are thrilled... to have taken this next step. Read more: https://bit.ly/AchieveNDA

Recently, our CEO, Rick Stewart, joined Justin Walsh, Director, Research Analyst at JonesTrading, to discuss the critical need for innovation in the smoking cessation market and ...how Achieve is working to address nicotine dependence.

Register and watch the full recording at…

Join us today at 5:30 PM ET as our CEO, Rick Stewart, presents Achieve Life Sciences' efforts to address nicotine dependence and support individuals on their journey to quit ...smoking.

Watch the live webcast and recording at: https://ir.achievelifesciences.com/

The ORCA-3 Phase 3 trial results for our investigational treatment, cytisinicline, recently published in @JAMAInternalMed, highlighted the need for new treatment options.
What do... you think is the biggest challenge to quitting smoking? Read more:

We’re excited to announce that Achieve Life Sciences will participate in the @Jefferies Global Healthcare Conference.

We’ll share updates on our progress addressing nicotine... dependence as a treatment for smoking cessation. Read more at https://bit.ly/AchieveJefferiesHealthcare…

Today, Achieve Life Sciences will present new data from our Phase 3 ORCA-3 trial results during an oral session at the 2025 @atscommunity’s International Conference.

For ...more details, read the full press release:

#ATS2025

We’re thrilled to be in San Francisco, attending the @atscommunity’s International Conference! Are you attending #ATS2025? If you’re interested in meeting with us, please ...send an email to ir@achievelifesciences.com.

Don’t miss Dr. Mark Rubinstein’s presentation on new data from our Phase 3 studies at the @atscommunity’s International Conference!

Learn how cytisinicline, our ...investigational treatment, is advancing smoking cessation research.

#ATS2025